RESUMO
BACKGROUND: Reliable and validated measures of skin disease severity are needed for cutaneous dermatomyositis (DM). Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI), Dermatomyositis Skin Severity Index (DSSI) and Cutaneous Assessment Tool (CAT) skin indices have been developed as outcome instruments. OBJECTIVES: We sought to demonstrate reliability and validity of the CDASI, and to compare the CDASI with other potential tools for use in measuring disease severity in cutaneous dermatomyositis. PATIENTS AND METHODS: CDASI has four activity and two damage measures, with scores from 0 to 148. DSSI assesses activity based on body surface area and severity on a scale of 0-72. CAT uses 21 activity and damage items, for a range of 0-175 for activity and 0-33 for damage. Ten dermatologists used the instruments to score the same 12-16 patients in one session. Global validation measures were administered to physicians and patients. RESULTS: Global validation measures correlated with the three outcome instruments (P < 0.0001). CAT displayed lower inter- and intrarater reliability relative to the CDASI. All scales correlate better with physician than patient global skin measures. CONCLUSIONS: It appears that the CDASI may be a useful outcome measure for studies of cutaneous DM. Further testing to compare responsiveness of all three measures is necessary.
Assuntos
Dermatomiosite/diagnóstico , Índice de Gravidade de Doença , Feminino , Humanos , Masculino , Variações Dependentes do Observador , Pennsylvania , Reprodutibilidade dos Testes , Inquéritos e Questionários/normasRESUMO
The development of neutralizing antibodies, or inhibitors, against infused factor VIII represents a significant complication of treatment for hemophilia A. Although it is likely that both genetic and environmental factors influence whether patients form inhibitors, correlations between types of factor VIII mutations and inhibitor development are becoming apparent. Approximately 20% of all patients with severe hemophilia A generate inhibitors. Of these inhibitor patients, 90% have inversions, large deletions or nonsense mutations of the factor VIII gene that would be predicted to eliminate production of factor VIII antigen. In contrast to patients with severe disease, inhibitor formation in patients with mild/moderate hemophilia A is rare. Inhibitor patients with mild/moderate disease typically have missense mutations that may cause local conformational changes within immunogenic domains of factor VIII and lead to production of dysfunctional antigen. Taken together, hemophilia A patients are predisposed to inhibitor development with mutations causing infused factor VIII to be perceived as either 1) a completely novel antigen or 2) an immunologically altered antigen.
Assuntos
Fator VIII/genética , Hemofilia A/imunologia , Fator VIII/imunologia , Genótipo , Hemofilia A/complicações , Hemofilia A/genética , Humanos , Isoanticorpos/imunologia , MutaçãoRESUMO
To test the hypothesis that factor VIII expressed in the epidermis can correct hemophilia A, we generated transgenic mice in a factor VIII-deficient background that express human factor VIII under control of the involucrin promoter. Mice from 5 transgenic lines had both phenotypic correction and plasma factor VIII activity. In addition to the skin, however, some factor VIII expression was detected in other tissues that have stratified squamous epithelia. To determine whether an exclusively cutaneous source of factor VIII could correct factor VIII deficiency, we grafted skin explants from transgenic mice onto mice that are double knockouts for the factor VIII and RAG-1 genes. Two graft recipients had plasma factor VIII activity of 4% to 20% of normal and improved whole blood clotting compared with factor VIII-deficient mice. Thus, expression of factor VIII from the epidermis can correct hemophilia A mice, thereby supporting the feasibility of cutaneous gene therapy for systemic disease. (Blood. 2000;95:2799-2805)
Assuntos
Fator VIII/genética , Terapia Genética/métodos , Hemofilia A/terapia , Transplante de Pele , Animais , Fator VIII/biossíntese , Genes RAG-1 , Proteínas de Homeodomínio/genética , Proteínas de Homeodomínio/metabolismo , Humanos , Camundongos , Camundongos Knockout , Camundongos Mutantes , Camundongos Transgênicos , Regiões Promotoras Genéticas , Precursores de Proteínas/genética , Proteínas Recombinantes/biossínteseRESUMO
A chromosomal translocation, t(4;11)-(q21;q23), is associated with an aggressive mixed-lineage leukemia. A yeast artificial chromosome was used to clone the chromosomal breakpoint of this translocation in the RS4;11 cell line. The breakpoint sequences revealed an inverted repeat bordered by a consensus site for topoisomerase II binding and cleavage as well as chi-like elements. The der(11) chromosome encodes a fusion RNA and predicted chimeric protein between the 11q23 gene MLL and a 4q21 gene designated AF4. The sequence of the complete open reading frame for this fusion transcript reveals the MLL protein to have homology with DNA methyltransferase, the Drosophila trithorax gene product, and the "AT-hook" motif of high-mobility-group proteins. An alternative splice that deletes the AT-hook region of MLL was identified. AF4 is a serine- and proline-rich putative transcription factor with a glutamine-rich carboxyl terminus. The composition of the complete MLL-AF4 fusion product argues that it may act through either a gain-of-function or a dominant negative mechanism in leukemogenesis.
Assuntos
Cromossomos Humanos Par 11 , Cromossomos Humanos Par 4 , Leucemia/genética , Proteínas Recombinantes de Fusão/biossíntese , Translocação Genética , Sequência de Aminoácidos , Sequência de Bases , Sítios de Ligação , Mapeamento Cromossômico , Cromossomos Fúngicos , Clonagem Molecular , DNA Topoisomerases Tipo II/metabolismo , Humanos , Dados de Sequência Molecular , Oligodesoxirribonucleotídeos , Poli A/isolamento & purificação , Poli A/metabolismo , RNA/isolamento & purificação , RNA/metabolismo , RNA Mensageiro , Sequências Repetitivas de Ácido Nucleico , Mapeamento por Restrição , Saccharomyces cerevisiae/genética , Homologia de Sequência de Aminoácidos , Homologia de Sequência do Ácido Nucleico , Células Tumorais CultivadasRESUMO
We have been studying a transformed derivative of a mouse fibroblast line (3T3DM) that stably maintains double minute chromosomes (DMs). In this report we describe a comprehensive analysis of the structure of the DMs within this cell line, utilizing a combination of long-range mapping via pulsed-field gel electrophoresis, screening of DM-enriched genomic libraries, and DM sizing using contour-clamped homogeneous electric field (CHEF) gel electrophoresis. Our data indicate that the minute particles in these cells exist as a homogeneous population of circular molecules, roughly 4 Mb in size, upon which three genes are amplified. One of these is the mdm2 oncogene, which has also been found to be amplified in a number of human sarcomas. Further, we present evidence that these three genes are arranged as two identical inverted repeat units linked by spacer regions of heterogeneous size. This work has led to the first model for the structure of an entire double minute particle containing an amplified oncogene; this model provides clues to later events occurring in the gene amplification process in tumor cells.
Assuntos
DNA/genética , Amplificação de Genes , Proteínas de Neoplasias/genética , Proteínas Nucleares , Oncogenes , Proteínas Proto-Oncogênicas , Células 3T3 , Animais , Linhagem Celular Transformada , Fosfatos de Dinucleosídeos/análise , Humanos , Camundongos , Camundongos Endogâmicos BALB C , Proteínas Proto-Oncogênicas c-mdm2 , RepliconRESUMO
We have carried out an analysis of amplified DNA sequences present in a tumorigenic mouse cell line, designated 3T3DM, to determine if the presence of cellular transforming activity is correlated with the elevated expression of any of the amplified genes. These studies utilized a selection protocol that allowed for DNA sequence amplification after the introduction of each gene into non-transformed recipient cells. Cell lines obtained from this selection protocol were assayed for tumorigenicity in nude mice. The results provided evidence that a gene, mdm2, that is amplified more than 50-fold in the 3T3DM cell line, induces tumorigenicity when experimentally overexpressed in NIH3T3 cells and in Rat2 cells. Analysis of the predicted amino acid composition of the mdm2 product(s) revealed features similar to those that have been shown to be functionally significant in certain DNA binding proteins/transcriptional activators. These include two potential metal binding motifs and a negatively charged domain rich in acidic amino acid residues. Overall, the data support the conclusion that mdm2 represents an evolutionarily conserved gene with tumorigenic potential and a predicted role in mechanisms of cellular growth control.
Assuntos
Regulação Neoplásica da Expressão Gênica , Proteínas de Neoplasias/genética , Neoplasias Experimentais/genética , Proteínas Nucleares , Oncogenes , Proteínas Proto-Oncogênicas , Células Tumorais Cultivadas/fisiologia , Sequência de Aminoácidos , Animais , Sequência de Bases , Evolução Biológica , Mapeamento Cromossômico , Clonagem Molecular , DNA/genética , Amplificação de Genes , Camundongos , Dados de Sequência Molecular , Proteínas Proto-Oncogênicas c-mdm2 , RNA Neoplásico/genética , Transfecção , Dedos de ZincoRESUMO
We have explored the structure and pattern of expression of a gene designated mdm-1, which is amplified 25-30-fold in transformed mouse cells containing numerous double minute particles. This gene is expressed in all mouse tissues examined but exhibits elevated and altered patterns of expression in the testis. Multiple transcripts are generated from the mdm-1 gene via mechanisms of alternative splicing and polyadenylation signal choice. These mRNAs have the potential to produce a minimum of three distinct protein products ranging in size from 25 to 77 kilodaltons. Antiserum generated against a synthetic peptide from the mdm-1 gene was used in immunoblotting studies and revealed that at least one of the protein products is present in the nucleus. This antiserum stained nuclear structures producing a distinct punctate or speckled pattern.